SLC5A2 and diabetes mellitus: However, while the cardiovascular benefits of SGLT-2 inhibitors in diabetics are well established, limited data exist regarding their real-world outcomes in hypertensive patients with and without diabetes, particularly in populations outside randomized trial settings.